TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)
Brief Summary: Tuberculosis (TB) continues to be one of the most serious bacterial infections worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB.

The new skin test is named C-Tb. Like the current tuberculin skin test, PPD, the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The investigators hope that this new C-Tb skin test will be more precise (specific) than the PPD test, as the PPD test e.g. may show a reaction if the person tested is BCG vaccinated.

The aim of this trial is to test the C-Tb skin test in volunteers suspected of having TB disease.

With focus on age, HIV status and CD4 count the following analyses are done (in an overall perspective):

* To compare the C-Tb test to a blood test, the QuantiFERON test.
* To compare the C-Tb test to the PPD test that is currently being used.
* To assess the safety of the C-Tb test.


Options:
A: Arm Label: 0.1 µg/0.1 mL C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U. Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: 2 T.U. Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg/0.1 mL C-Tb | Intervention Type: BIOLOGICAL; Name: 2 T.U. Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U. Tuberculin PPD RT 23 SSI
B: Arm Label: 0.1 µg C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tuberculin PPD RT 23 SSI | Arm Label: 0.1 µg C-Tb / 2 T.U Tuberculin PPD; Type: EXPERIMENTAL; Interventions: Biological: C-Tb / Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg C-Tb | Intervention Type: BIOLOGICAL; Name: Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb / Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 0.1 µg C-Tb / 2 T.U Tuberculin PPD
C: Arm Label: Facility-based screening; Type: EXPERIMENTAL; Interventions: Other: Active TB case finding | Arm Label: Contact screening; Type: EXPERIMENTAL; Interventions: Other: Active TB case finding | Intervention Type: OTHER; Name: Active TB case finding; Assigned to Arm(s): Contact screening, Facility-based screening
D: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation
Brief Summary: Based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant. Our study is designed to determine if tight blood sugar control around the time of kidney transplant will improve short term graft function.


Options:
A: Arm Label: Glucagon-like peptide-1 (GLP-1); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucagon-like peptide-1 (GLP-1), Other: Hyperglycemic clamp | Arm Label: Isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Isotonic saline, Other: Hyperglycemic clamp | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucagon-like peptide-1 (GLP-1); Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1) | Intervention Type: OTHER; Name: Isotonic saline; Assigned to Arm(s): Isotonic saline | Intervention Type: OTHER; Name: Hyperglycemic clamp; Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1), Isotonic saline
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
C: Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians
Brief Summary: To determine if physicians who complete brief tasks intended to promote meaning in work and job satisfaction, foster teamwork and social support at work, nuture personal relationships and work-life balance, recognize and build on personal strengths, encourage effective problem solving, and promote positive emotions have improved resilience, meaning in work, and engagement at work.


Options:
A: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
B: Arm Label: MCAT Supervision Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindful-Compassion Art Therapy Supervision | Arm Label: Waitlist Control Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindful-Compassion Art Therapy Supervision | Intervention Type: BEHAVIORAL; Name: Mindful-Compassion Art Therapy Supervision; Assigned to Arm(s): MCAT Supervision Group, Waitlist Control Group
C: Arm Label: Resiliency Training; Type: EXPERIMENTAL; Interventions: Behavioral: Disaster Worker Resiliency Training | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Disaster Worker Resiliency Training; Assigned to Arm(s): Resiliency Training
D: Arm Label: Intervention App; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention App | Arm Label: Control App; Type: SHAM_COMPARATOR; Interventions: Behavioral: Intervention App | Intervention Type: BEHAVIORAL; Name: Intervention App; Assigned to Arm(s): Control App, Intervention App

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians
Brief Summary: To determine if physicians who complete brief tasks intended to promote meaning in work and job satisfaction, foster teamwork and social support at work, nuture personal relationships and work-life balance, recognize and build on personal strengths, encourage effective problem solving, and promote positive emotions have improved resilience, meaning in work, and engagement at work.


Options:
A: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
B: Arm Label: Mobile Video Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Stress management counseling | Arm Label: Offline Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management counseling | Arm Label: Selfcare; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress management counseling; Assigned to Arm(s): Mobile Video Counseling, Offline Counseling
C: Arm Label: Mindfulness-based self-care; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based self care | Arm Label: Life as usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based self care; Assigned to Arm(s): Mindfulness-based self-care
D: Arm Label: Group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Manualized Therapy | Arm Label: Control Group; Type: OTHER; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Manualized Therapy; Assigned to Arm(s): Group therapy | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians
Brief Summary: To determine if physicians who complete brief tasks intended to promote meaning in work and job satisfaction, foster teamwork and social support at work, nuture personal relationships and work-life balance, recognize and build on personal strengths, encourage effective problem solving, and promote positive emotions have improved resilience, meaning in work, and engagement at work.


Options:
A: Arm Label: SB-APP Psychotherapy; Type: EXPERIMENTAL; Interventions: Other: SB-APP | Arm Label: TAU treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: SB-APP; Assigned to Arm(s): SB-APP Psychotherapy | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): TAU treatment
B: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
C: Arm Label: Mindful Awareness Practices (MAPs); Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Awareness Practices (MAPs) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Awareness Practices (MAPs); Assigned to Arm(s): Mindful Awareness Practices (MAPs)
D: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians
Brief Summary: To determine if physicians who complete brief tasks intended to promote meaning in work and job satisfaction, foster teamwork and social support at work, nuture personal relationships and work-life balance, recognize and build on personal strengths, encourage effective problem solving, and promote positive emotions have improved resilience, meaning in work, and engagement at work.


Options:
A: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Intervention; Assigned to Arm(s): Mindfulness
B: Arm Label: Cohort 1; Type: OTHER; Interventions: Behavioral: Three Good Things, Behavioral: Gratitude, Behavioral: Random Acts of Kindess, Behavioral: Awe, Behavioral: 1 Good Chat | Arm Label: Cohort 2; Type: OTHER; Interventions: Behavioral: Three Good Things, Behavioral: Gratitude, Behavioral: Random Acts of Kindess, Behavioral: Awe, Behavioral: 1 Good Chat | Arm Label: Cohort 3 (July cohort) WISER 2.0; Type: EXPERIMENTAL; Interventions: Behavioral: Three Good Things, Behavioral: Gratitude, Behavioral: Random Acts of Kindess, Behavioral: Awe, Behavioral: 1 Good Chat | Intervention Type: BEHAVIORAL; Name: Three Good Things; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 (July cohort) WISER 2.0 | Intervention Type: BEHAVIORAL; Name: Gratitude; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 (July cohort) WISER 2.0 | Intervention Type: BEHAVIORAL; Name: Random Acts of Kindess; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 (July cohort) WISER 2.0 | Intervention Type: BEHAVIORAL; Name: Awe; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 (July cohort) WISER 2.0 | Intervention Type: BEHAVIORAL; Name: 1 Good Chat; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 (July cohort) WISER 2.0
C: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
D: Arm Label: Active ABMT8; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active ABMT8 | Arm Label: Active ABMT4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active ABMT4 | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: BEHAVIORAL; Name: Active ABMT8; Assigned to Arm(s): Active ABMT8 | Intervention Type: BEHAVIORAL; Name: Active ABMT4; Assigned to Arm(s): Active ABMT4 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies
Brief Summary: The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. The investigators propose a clinical trial with the objective to identify effective strategies to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.

The investigators intend to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries. These 2 strategies are affordable, easy to apply, and they present very few maternal-fetal secondary effects.


Options:
A: Arm Label: Pessary; Type: EXPERIMENTAL; Interventions: Device: Bioteque cup pessary | Arm Label: No pessary; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bioteque cup pessary; Assigned to Arm(s): Pessary
B: Arm Label: Vaginal micronized progesterone; Type: EXPERIMENTAL; Interventions: Drug: Vaginal micronized progesterone | Arm Label: Cervical pessary; Type: ACTIVE_COMPARATOR; Interventions: Device: Cervical pessary | Intervention Type: DRUG; Name: Vaginal micronized progesterone; Assigned to Arm(s): Vaginal micronized progesterone | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical pessary
C: Arm Label: Intravaginal progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prometrium | Arm Label: Intravaginal progesterone and pessary; Type: EXPERIMENTAL; Interventions: Drug: Prometrium, Device: Dr. Arabin, cerclage pessary perforated | Intervention Type: DRUG; Name: Prometrium; Assigned to Arm(s): Intravaginal progesterone, Intravaginal progesterone and pessary | Intervention Type: DEVICE; Name: Dr. Arabin, cerclage pessary perforated; Assigned to Arm(s): Intravaginal progesterone and pessary
D: Arm Label: Vaginal progesterone and Pessary; Type: EXPERIMENTAL; Interventions: Drug: Arabin Pessary | Arm Label: Vaginal progesterone only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arabin Pessary | Intervention Type: DRUG; Name: Arabin Pessary; Assigned to Arm(s): Vaginal progesterone and Pessary, Vaginal progesterone only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Brief Summary: Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).

Primary Objective of the study:

* To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in high cardiovascular (CV) risk participants with hypercholesterolemia

Secondary Objectives:

* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points
* To evaluate the effect of alirocumab on other lipid parameters
* To evaluate the safety and tolerability of alirocumab


Options:
A: Arm Label: Alirocumab 75 mg/up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), Drug: alirocumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LMT (atorvastatin, simvastatin, or rosuvastatin); Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: alirocumab; Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: LMT | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: LMT | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LMT; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
D: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Pessary Interval for Care (EPIC Study): Patient Preference for 3 Verus 6 Month Follow-up
Brief Summary: Objectives: Pelvic organ prolapse (POP) is a common condition for which pessaries are commonly used in conservative treatment. Despite their prevalence, there is no literature to guide the management of pessaries. Our objective is to determine whether patients managed with a pessary for POP are more satisfied with follow-up at 3 or 6 month intervals and if there is any difference in complications rates between the two groups.

Hypothesis: The investigators hypothesize that there will be higher patient satisfaction in the group randomized to 6 month follow-up intervals and that there will be no difference in complication rates between the two follow-up groups.

Method: The investigators will conduct a prospective randomized control trial comparing patient satisfaction and complication rates between patients with pessaries randomized to either 3 or 6 month follow-up intervals over 1 year.


Options:
A: Arm Label: PFMT plus routine pessary management; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Arm Label: Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Intervention Type: OTHER; Name: PFMT; Assigned to Arm(s): Lifestyle, PFMT plus routine pessary management
B: Arm Label: Pessary Check at 3 months; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 6 month Pessary Check; Type: EXPERIMENTAL; Interventions: Other: 6 month follow up for pessary check in the clinic setting | Intervention Type: OTHER; Name: 6 month follow up for pessary check in the clinic setting; Assigned to Arm(s): 6 month Pessary Check
C: Arm Label: Estrogen Cream; Type: EXPERIMENTAL; Interventions: Drug: Conjugated Estrogens Cream | Arm Label: Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Cream | Intervention Type: DRUG; Name: Conjugated Estrogens Cream; Assigned to Arm(s): Estrogen Cream | Intervention Type: DRUG; Name: Placebo Cream; Assigned to Arm(s): Placebo Cream
D: Arm Label: Vaginal estrogen cream; Type: EXPERIMENTAL; Interventions: Drug: Vaginal Cream with Applicator [Dose Form] | Arm Label: vaginal placebo cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vaginal Cream with Applicator [Dose Form] | Intervention Type: DRUG; Name: Vaginal Cream with Applicator [Dose Form]; Assigned to Arm(s): Vaginal estrogen cream, vaginal placebo cream

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Targeting Acute Congestion With Tolvaptan In Congestive Heart Failure Study
Brief Summary: The primary objective of this study is to compare the effects of oral Tolvaptan vs. placebo as an adjunct to fixed dose IV furosemide on dyspnea relief in patients with acute decompensated heart failure

The primary hypothesis is that the addition of oral Tolvaptan to fixed dose furosemide will be more effective at relieving dyspnea than fixed dose furosemide alone


Options:
A: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A
B: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR121463B; Assigned to Arm(s): N/A

Answer: B